coronary artery disease

Latest Headlines

Latest Headlines

Danish trial results show stem cells improve failing hearts

Results from a clinical trial of 59 patients with chronic ischemic heart disease and severe heart failure found that a new stem cell treatment improved heart pump function compared to the placebo group.

OrbusNeich starts up a U.S.-Japan trial of its dual-therapy stent

OrbusNeich has enrolled its first patient in a two-country proof-of-concept study for its innovative dual-therapy stent.

Biotronik kicks off absorbable stent trial as market crowds

Germany's Biotronik has treated its first patient in a multi-center trial of its bioabsorbable vascular scaffold, a study aimed at winning a CE mark for the coronary artery disease-treating device.

Abbott rides next-gen Xience stent into Japan

Abbott Laboratories won Japanese approval for its Xience Xpedition drug-eluting stent, plotting to launch the device in one of the world's largest markets and pad sales in its flagging vascular business.

Abbott CE mark covers extra-long stent size

In the fiercely competitive global stent market, Abbott seems to view size as mattering most.

Elixir snags CE mark for dissolvable stent

While Abbott Laboratories leads the way in the dissolvable stent market, California's Elixir Medical is right on its heels, winning CE mark approval for the DESolve device.

Cardiovascular Systems completes PMA submission

Cardiovascular Systems can now add a PMA submission to its aggressively confident 2013. The Minnesota company said it completed a premarket approval application with the FDA for a new device designed to treat calcified coronary arteries.

Study: Excess weight-loss risks harming CRT-D heart failure patients

Researchers are warning that some overweight heart failure patients with CRT-D implants (cardiac resynchronization therapy with defibrillation) shouldn't necessarily shed those extra pounds. If they do, the scientists found in a massive study of nearly 1,000 patients, these folks could develop even worse heart failure or die.

CardioDx CAD Dx passes another post-marketing test

CardioDx is promoting yet another post-marketing study whose data may help the company's gene expression test for obstructive coronary artery disease reach more patients, better compete with the standard of care build and also build vital market share.

TriReme nails $18M financing to advance PAD treatment devices

TriReme Medical pulled in an $18 million financing round to propel new product development and broaden the commercial sales of its coronary and peripheral artery disease treatment devices.